PRECIGEN, INC. Tax Withholding Paid on Stock Awards
PRECIGEN, INC. (PGEN) reported Tax Withholding Paid on Stock Awards of $1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-04
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $1.35M, a 3.61% increase year-over-year.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $146.00K, a 69.20% decline year-over-year.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $1.78M.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $0.00.
- PRECIGEN, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.50M 10-Q · filed 2026-08-04 | $1.50M derived: sum of 3 quarters · filed 2026-08-04 | $1.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $146.00K 10-Q · filed 2026-05-13 | $146.00K derived: sum of 2 quarters · filed 2026-05-13 | $146.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $1.30M derived: sum of 3 quarters · filed 2026-08-04 | $1.78M 10-K · filed 2026-03-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.30M derived: sum of 2 quarters · filed 2026-08-04 | $1.78M 10-Q · filed 2025-11-13 | $1.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.78M 10-Q · filed 2026-08-04 | $1.78M derived: sum of 3 quarters · filed 2026-08-04 | $1.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $474.00K 10-Q · filed 2026-05-13 | $474.00K derived: sum of 2 quarters · filed 2026-05-13 | $474.00K derived: sum of 3 quarters · filed 2026-05-13 | $474.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |